1. Home
  2. Sistema de Salut de Catalunya
  3. Vall d'Hebron Institut d'Oncologia – VHIO
  4. Articles científics - VHIO
  5. View Item

TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer

To access the full text documents, please follow this link: http://hdl.handle.net/11351/6446

Author

Tolaney, Sara M

Arteaga, Carlos

Cortés Castan, Javier

Rugo, Hope

Bardia, Aditya

Sohn, Joohyuk

Other authors

Institut Català de la Salut

[Rugo HS] Department of Medicine (Hematology/Oncology), University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94115, USA. [Bardia A] Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. [Tolaney SM] Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA. [Arteaga C] Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA. [Cortes J] Medical Oncology Department, IOB Institute of Oncology, Quirosalud Group, Madrid & Barcelona. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Sohn J] Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea

Vall d'Hebron Barcelona Hospital Campus

Publication date

2021-10-22T09:06:05Z

2021-10-22T09:06:05Z

2020-04



Share

Abstract

HER2-negative; Metastatic breast cancer; Sacituzumab govitecan

HER2 negatiu; Càncer de mama metastàsic; Sacituzumab govitecan

HER2 negativo; Cáncer de mama metastásico; Sacituzumab govitecan

Patients with HR+/HER2- metastatic breast cancer (MBC) whose cancers have progressed despite conventional therapies represent an unmet clinical need. Trop-2, a transmembrane calcium signal transducer, is highly expressed in MBC and plays a role in tumor growth and progression. Sacituzumab govitecan (SG) is a novel antibody–drug conjugate comprising an Trop-2 antibody coupled to SN-38, the active metabolite of irinotecan, via a unique hydrolyzable linker. SG has demonstrated promising activity in a Phase I/II IMMU-132-01 basket study in heavily pretreated solid tumors, including HR+/HER2- MBC. We describe the registrational Phase III TROPiCS-02 study (NCT03901339), evaluating SG versus treatment of physician’s choice in HR+/HER2- MBC.

Document Type

Article

Published version

Language

English

Subjects and keywords

Mama - Càncer - Quimioteràpia; Metàstasi; DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms; Other subheadings::Other subheadings::Other subheadings::/drug therapy; DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica

Publisher

Future Medicine

Related items

Future Oncology;16(12)

https://doi.org/10.2217/fon-2020-0163

Recommended citation

This citation was generated automatically.

Export

DIDL MARC MARC_CCUC METS OAI_DC ORE QDC RDF

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International

http://creativecommons.org/licenses/by-nc-nd/4.0/

This item appears in the following Collection(s)

Articles científics - VHIO [468]